Molecular pathology for classification of tumors and for efficacy prediction of qualified therapies can be a rapidly rising area. g., PARP inhibitor) being a consequence of knowledge on the use of PARP inhibitors in BRCA1/two mutation carriers with Highly developed breast cancer (LoE 1b/GR B/In the past+) [six] (see https://tommyy974tcj1.blog5star.com/profile